14-3-3 Protein Dimerization Inhibitors for Cancer Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapeutic agents targeting 14-3-3 proteins have limited therapeutic potential for diseases such as cancer and wound healing due to their inability to effectively modulate 14-3-3 protein functionality.

Innovation Solution

Administering agents that inhibit the dimerization of 14-3-3 proteins, specifically cationic lipids with a heterocyclic head group and a hydrophobic tail group of at least 12 carbon atoms, to modulate 14-3-3 protein functionality, thereby preventing or treating diseases and promoting apoptosis or wound healing.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If small molecules are used to modulate 14-3-3 activity, then in vitro activity is achieved, but therapeutic potential is limited

Engineering Contradiction:

Improvetherapeutic potentialVSAvoidefficacy in treatment

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent uses dimerization inhibitors as intermediary agents that disrupt the 14-3-3 protein dimer interface, preventing the formation of functional dimers. This intermediary approach blocks the interaction between 14-3-3 proteins and their client proteins, thereby modulating 14-3-3 activity with improved therapeutic potential compared to direct small molecule modulators

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention extracts and targets the specific dimerization interface of 14-3-3 proteins as the critical functional element. By designing inhibitors that specifically bind to and block the dimer interface (taking out the dimerization capability), the patent achieves potent modulation of 14-3-3 functionality with enhanced therapeutic efficacy

Inventive Principle:

Principle #2Taking out (Extraction)

2Reliability

If 14-3-3 protein functionality is modulated to treat cancer, then sensitivity to treatment increases, but proliferation and survival signaling are activated

Engineering Contradiction:

Improvesensitivity to treatmentVSAvoidproliferative and survival signaling

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

Instead of activating 14-3-3 proteins to inhibit cancer (which would activate harmful survival signaling), the patent inverts the approach by using dimerization inhibitors to block 14-3-3 function. This inversion selectively disrupts pro-survival 14-3-3 interactions in cancer cells while sparing normal physiological functions, achieving treatment sensitivity without harmful signaling activation

Inventive Principle:

Principle #13The other way round (Inversion)

Data Source

PatentUS10583115B2Modulators of 14-3-3 functionality and uses thereof

Publication Date: 2020.03.10 ADELAIDE UNIVERSITY

AI summary

The present disclosure relates to modulators of 14-3-3 functionality and their use in methods and compositions for preventing and/or treating various diseases, conditions and states, such as cancer and healing of wounds. Certain embodiments of the present disclosure provide a method of preventing and/or treating a disease, condition or state in a subject associated with altered 14-3-3 protein functionality and/or which would benefit from altering 14-3-3 functionality, the method comprising administering to the subject an effective amount of an agent which inhibits dimerization of the 14-3-3 protein, thereby preventing and/or treating the disease, condition or state in the subject.